The product matters
Kratom can refer to leaf powder, capsules, extracts and a changing range of concentrated products. The FDA distinguishes the small amounts of 7-hydroxymitragynine naturally present in kratom leaf from products with added or enhanced 7-OH. These are not interchangeable descriptions of the same exposure.
A tablet, shot or gummy may be marketed with kratom language even when concentrated 7-OH is the important ingredient. The FDA warns that some products do not clearly or accurately state their 7-OH content.
Bring what you know
A clear photo of the front, ingredients and serving information is a practical place to start. Tell the team if you use more than one product or have changed products recently.
- Product and brand name, plus the package if available.
- Whether it is powder, capsules, an extract, a liquid, a gummy or a tablet.
- What the label says about mitragynine, 7-OH or other ingredients.
- Your usual pattern of use and what happens when a dose is delayed.
Ask about the exact formulation
Try: ‘I use this product. Does your clinical team assess and treat people using it?’ That is more useful than asking only whether a center treats kratom.
Do not convert leaf grams and labeled 7-OH milligrams into an equivalent dose yourself. Give the clinician the original information. FDA warnings about kratom and concentrated 7-OH also mean that ‘natural’ should not be read as a safety guarantee.
Sources
General opioid-treatment information does not establish that a particular medicine is approved for kratom or 7-OH dependence or that a particular approach fits you. Discuss your goals with a clinician.